Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2004

View Archived Issues

BMS highlights Q1 developments

Amylin achieves first three of corporate goals for 2004 during first quarter

SR-142801 alters endocrine stress response in patients with panic disorder

Preclinical evidence of the inhibitory effects of AZD-0865 on acid output

Phase II clinical data on the efficacy of tolevamer in CDAD

Therapeutic benefits of sargramostim in moderate to severe Crohn's disease

Ruboxistaurin mesilate may improve symptoms of diabetic peripheral neuropathy

Positive results reported from phase III trial of alvimopan in opioid-induced bowel dysfunction

Study confirms previous findings that bicifadine offers fast-acting and safe treatment of pain

European Commission officially adopts EMEA positive opinion on nimesulide

IDEA-070 shows excellent efficacy in treatment of UVB-induced skin inflammation

BioMS Medical seeks clearance to begin pivotal trial of MBP-8298 in Canada

FDA approves DepoDur for treatment of pain

Johnson & Johnson acquires Egea Biosciences

NovaRx completes enrollment ahead of schedule in phase II trial of cancer treatment

BTG in-licenses novel antitumor agents

Cerus announces phase IIIc results for Intercept Blood System

Phase II trial of clofarabine in adult acute leukemia exceeds expectations

Neurochem updates clinical pipeline progress

Isotechnika receives clearance to initiate phase I trial of TAFA-93 in Canada

Phase II/III trial of AIC for treatment of ragweed allergy now fully enrolled

Progesterone cream ineffective as postmenopausal bone loss prophylaxis

Ospemifene reduces markers of bone turnover in postmenopausal women

Preliminary evidence for the efficacy of basiliximab in ulcerative colitis

Tigecycline potent, broadly active in vitro

3-Dimensional Pharmaceuticals claims new tyrosine kinase inhibitors and their use

New p38 MAP kinase inhibitors in early development at Celltech

Bayer patents a guanylate cyclase activator and its use in cardiovascular disorders

Three related series of gamma-secretase inhibitors and their use in AD therapy

Novel factor Xa inhibitors covered by BMS patent

Pfizer researchers present another series of HIV RT inhibitors

Novel CCR5 antagonists for transplant rejection, autoimmune diseases, etc.